### Prior Authorization Request Form for

## Pirtobrutinib (Jaypirca)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

#### The completed form may be faxed to 855-273-5735

OR

The patient may attach the completed form to the prescription and **mail** it to: Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

#### QUESTIONS? Call 1-877-880-7007

Step	Please complete patient and physician information (please print):						
1	Patient Name: Physic			ian Name:			
	Address:			Address:			
	Sponsor ID #						
					ure Fax #:		
Step			te the clinical assessment:				
2	1.	Is the patient GREATER THAN or EQUAL to 18 years		□ Yes	□ No		
-		of age?		,	Proceed to question <b>2</b>	STOP	
						Coverage not approved	
	2.		quested medication being tion with a hematologist o		□ Yes	□ No	
				Proceed to question 3	STOP		
						Coverage not approved	
	3.		e patient have pathologica		□ Yes	□ No	
		relapsed or refractory mantle cell lymphoma (MCL)?		Proceed to question 6	Proceed to question 4		
	4.	What is	the diagnosis or indicatior	1?			
					Proceed	to question <b>5</b>	
	5.		agnosis cited in the Nation		□ Yes	□ No	
		Cancer Network (NCCN) guidelines as a category 1, 2A, or 2B recommendation?		Proceed to question 6	STOP		
		·				Coverage not approved	
	6.		patient be monitored for b		□ Yes	□ No	
			ng opportunistic infection) nias, secondary primary m		Proceed to question <b>7</b>	STOP	
		cytopeni		<b>J</b>		Coverage not approved	
	7.	Will the	patient use sun protection	in sun-exposed	□ Yes	□ No	
		areas?			Proceed to question 8	STOP	
						Coverage not approved	
					<u> </u>		

## US Family Health Plan Prior Authorization Request Form for **Pirtobrutinib (Jaypirca)**

8.	What is the patient's gender?	□ Female	□ Male
		Proceed to question 9	Sign and date below
9.	Is the patient of childbearing potential?	□ Yes	🗆 No
		Proceed to question <b>10</b>	Sign and date below
10.		□ Yes	□ No
	least 1 week after cessation of therapy?	Proceed to question <b>11</b>	STOP
			Coverage not approved
11.	Is the patient pregnant?	□ Yes	□ No
		STOP	Proceed to question 12
		Coverage not approved	
12.		□ Yes	🗆 No
	by negative nCG (numan chorionic gonadotropin)?	Proceed to question 13	STOP
			Coverage not approved
13.		□ Yes	□ No
	and for at least 1 week after the cessation of treatment?	Sign and date below	STOP
			Coverage not approved
	9. 10. 11. 12.	<ul> <li>9. Is the patient of childbearing potential?</li> <li>10. Does the patient agree to use effective contraception before starting treatment, during treatment and for at least 1 week after cessation of therapy?</li> <li>11. Is the patient pregnant?</li> <li>12. Has it been confirmed that the patient is not pregnant by negative hCG (human chorionic gonadotropin)?</li> <li>13. Will the patient avoid breastfeeding during treatment and for at least 1 week after the cessation of</li> </ul>	1       Initial end of the patient of statut       Proceed to question 9         9. Is the patient of childbearing potential?       Image: Yes         10. Does the patient agree to use effective contraception before starting treatment, during treatment and for at least 1 week after cessation of therapy?       Image: Yes         11. Is the patient pregnant?       Image: Yes         12. Has it been confirmed that the patient is not pregnant by negative hCG (human chorionic gonadotropin)?       Image: Yes         13. Will the patient avoid breastfeeding during treatment and for at least 1 week after the cessation of       Image: Yes

# 3

Prescriber Signature

Date

[09 August 2023]